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Abstract
Pulmonary fibrosis results from the excessive deposition of collagen fibers and scarring in the 
lungs with or without an identifiable cause. The mechanism(s) underlying lung fibrosis 
development is poorly understood, and effective treatment is lacking. Here we compared mouse 
lung fibrosis induced by pulmonary exposure to prototypical particulate (crystalline silica) or 
soluble chemical (bleomycin or paraquat) fibrogenic agents to identify the underlying 
mechanisms. Young male C57BL/6J mice were given silica (2 mg), bleomycin (0.07 mg), or 
paraquat (0.02 mg) by pharyngeal aspiration. All treatments induced significant inflammatory 
infiltration and collagen deposition, manifesting fibrotic foci in silica-exposed lungs or diffuse 
fibrosis in bleomycin or paraquat-exposed lungs on day 7 post-exposure, at which time the lesions 
reached their peaks and represented a junction of transition from an acute response to chronic 
fibrosis. Lung genomewide gene expression was analyzed, and differential gene expression was 
confirmed by quantitative RT-PCR, immunohistochemistry, and immunoblotting for 
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representative genes to demonstrate their induced expression and localization in fibrotic lungs. 
Canonical signaling pathways, gene ontology, and upstream transcription networks modified by 
each agent were identified. In particular, these inducers elicited marked proliferative responses; at 
the same time, silica preferentially activated innate immune functions and the defense against 
foreign bodies, whereas bleomycin and paraquat boosted responses related to cell adhesion, 
platelet activation, extracellular matrix remodeling, and wound healing. This study identified, for 
the first time, the shared and unique genes, signaling pathways, and biological functions regulated 
by particulate and soluble chemical fibrogenic agents during lung fibrosis, providing insights into 
the mechanisms underlying human lung fibrotic diseases.
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Introduction
Pulmonary fibrosis is an irreversible stage of pathologic development in a variety of lung 
diseases (Husain and Kumar 2005). Pulmonary fibrosis can occur as a result of an existing 
lung condition, such as chronic lung Inflammation, or without a known cause, as 
exemplified by idiopathic pulmonary fibrosis (IPF), but more often is caused by exposure to 
a fibrogenic agent, such as inhaled particles, fibers, and microbes, as well as soluble 
chemicals that selectively accumulate in the lungs and damage lung tissues (Meltzer and 
Noble 2008; Morgan and Seaton 1995; Raghu et al. 2011; Thomas and Kelley 2010). 
Despite this enormous etiologic diversity, fibrosis in the lungs shares considerable common 
pathologic features characterized by excessive and progressive deposition of collagen fibers 
in the lung interstitial space and scarring of the lungs, which lead to destruction of alveolar 
and airway structures and loss of respiratory capacity (Husain and Kumar 2005; Morgan and 
Seaton 1995). The mechanism(s) underlying pulmonary fibrosis is poorly understood, which 
hampers drug discovery and drug development for treating lung fibrosis. As a result, no 
effective therapy against human lung fibrotic diseases is available.
In the case of IPF, a chronic, progressive, and ultimately lethal human lung fibrotic disease, 
lung transplant remains to be the only lifesaving treatment and the median survival of IPF 
patients is merely 2–5 years after diagnosis (Meltzer and Noble 2008; Raghu et al. 2011). 
The pathologic features of IPF include the presence of mild-to-moderate Inflammation with 
inflammatory infiltration, injury and hyperplasia of alveolar epithelial cells, enhanced 
deposition of extracellular matrix, thickened alveolar septa, formation of scars and 
fibroblastic foci, and temporally heterogeneous fibrotic remodeling of lung structures 
(Meltzer and Noble 2008; Raghu et al. 2011). Some of these characteristics can be observed 
in animal models of induced lung fibrosis (Degryse and Lawson 2011; Moeller et al. 2008).
Bleomycin is a glycopeptide anti-tumor antibiotic that effectively treats certain cancers. 
Exposure to bleomycin, either systemically or locally, induces pulmonary fibrosis as a side 
effect of anti-cancer therapy. Bleomycin induces lung fibrosis in rodents, which has been 
used as an animal model of choice for the study of human IPF during the past decade 
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(Moore and Hogaboam 2008). In the murine model, bleomycin-induced fibrosis develops 
quickly, but is self-limiting after several weeks of treatment; moreover, drug development 
based on the single-dose bleomycin-induced lung fibrosis model has not produced clinically 
effective therapeutics for treating IPF (Degryse and Lawson 2011; Moeller et al. 2008).
Silica is an abundant mineral that commonly exists in the earth's crust and surface in the 
forms of sand, rock, and mineral ore. Pulmonary exposure to crystalline silica dusts causes 
the human lung disease called silicosis, characterized by the occurrence of lung 
Inflammation and fibrosis, decline of lung functions, and premature death (Morgan and 
Seaton 1995). Exposure to silica typically takes place during industrial activities, such as 
mining, manufacturing, and construction, through inhalation of silica-containing dusts, 
though non-occupational exposure to silica also takes place (Morgan and Seaton 1995; 
Thomas and Kelley 2010). Like IPF, no curative treatment for silicosis is available. In 
animals, inhalation of silica results in pulmonary inflammatory responses, such as activated 
alveolar macrophages and increased polymorphonuclear leukocytes in the bronchoalveolar 
space; pulmonary fibrotic responses, such as elevated collagen deposition and fibrotic 
nodule formation; and prominent lung tissue damage (Ohtsuka et al. 2006; Porter et al. 
2004).
Paraquat (N, N-dimethyl-4, 4′-bipyridinium dichloride) is the second most widely used 
herbicide globally, but is a potent lung toxicant causing lung fibrosis by accumulating in 
lung epithelial cells and damaging lung structures (Dinis-Oliveira et al. 2008), similarly to 
bleomycin. The lung toxicity of paraquat is dominant and lethal and is believed to be 
mediated through redox cycling and intracellular oxidative stress (Bus and Gibson 1984). 
Formation of intra-alveolar fibrosis is a major cause of paraquat-induced mortality, for 
which no effective treatment has been found (Dinis-Oliveira et al. 2008; Gawarammana and 
Buckley 2011).
From a mechanistic point of view, the fibrotic response to exposure of particles (silica), 
fibers (asbestos and nanotubes), and volumetric biological materials (helminth eggs), 
resembles the tissue response to foreign body deposition in the lungs. On the other hand, 
lung fibrosis induced by soluble chemicals, such as bleomycin and paraquat, is believed to 
be derived directly from damaging the alveolar and airway cells by the chemicals (Bus and 
Gibson 1984; Dong and Ma 2015; Husain and Kumar 2005; Moore and Hogaboam 2008; 
Morgan and Seaton 1995). Nonetheless, in both scenarios, the pulmonary lesions include an 
acute-phase response characterized by inflammatory infiltration and tissue damage, and 
chronic fibrosis development marked by interstitial fibrosis, granuloma formation, and 
scarring of the lungs. The acute-phase inflammatory lesion often reaches its peak after 1 
week, but reduces in intensity substantially after 14 days post-exposure to a single-dose 
treatment (Bissonnette and Rola-Pleszczynski 1989; Bus and Gibson 1984; Dong et al. 
2015; Huaux et al. 2003; Rabolli et al. 2011), though repeated exposures can result in 
sustained inflammatory lesions alongside fibrosis (Porter et al. 2004). This prominent 
morphologic switch from acute-to-chronic pathology suggests the activation of critical 
cellular and molecular events, including programmed transcription of genes, at the acute-to-
chronic junction, to bring about the drastic pathologic transition and disease progression. 
Elucidating the molecular mechanisms that mediate or control the acute-to-chronic transition 
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in the development of lung fibrosis would reveal new mechanistic aspects of the 
pathogenesis of both induced and idiopathic lung fibrotic diseases.
We attempted to address these issues by analyzing and comparing the genome-wide gene 
expression profiles in experimental lung fibrosis models induced by silica, bleomycin, and 
paraquat, which are prototypical particulate or soluble chemical fibrogenic inducers. We 
chose day 7 post-exposure, at which time the acute responses appear to have reached their 
peaks with a similar intensity, for microarray analysis, in order to gain insights into the 
critical pathways and mediators that govern the transition from acute-to-chronic pathologic 
development. The analyses identified both shared and distinct pathways and mechanisms for 
the development of lung fibrosis induced by the inducers. Therefore, our study uncovered 
the affected molecules and signaling pathways that might function in the onset of lung 
fibrosis in general or in a fibrogenic agent-specific man-ner, which offer new clues to 
understanding the molecular mechanisms underlying lung fibrosis in humans.
Materials and methods
Animals and treatment
Eight- to 10-week-old specific pathogen-free male C57BL/6J mice purchased from The 
Jackson Laboratory (Bar Harbor, ME, USA) were used throughout this study. Mice were 
maintained in an accredited, specific pathogen-free and environmentally controlled facility 
at the National Institute for Occupational Safety and Health. Mice were housed in 
polycarbonate ventilated cages with HEPA-filtered air and 12-h fluorescent lighting, and 
were fed with Harlan Teklad Rodent Diet 7913 (Indianapolis, IN, USA) with tap water ad 
libitum. All animal experiments were performed in accordance with the guidelines approved 
by the Institutional Animal Care and Use Committee.
Mice were treated with the following agents: (a) saline (Baxter Healthcare Corporation, 
Deerfield, IL, USA) as solvent control; (b) silica (MIN-U-SIL 5, US Silica, Berkeley 
Springs, WV, USA) at 2 mg/mouse; (c) bleomycin (bleomycin sulfate, Enzo Life Sciences, 
Farmingdale, NY, USA) at 0.07 mg/mouse; or (d) paraquat (Thermo Fisher Scientific, 
Rockford, IL, USA) at 0.02 mg/mouse; six to eight mice per group were used depending on 
the experiments performed. All reagents were prepared in saline. Mice were anesthetized 
with isoflurane (Piramal Healthcare, Bethlehem, PA, USA) and were given the above dose 
in 50 μl saline by pharyngeal aspiration following established procedures (Dong et al. 2015; 
Porter et al. 2010). Mouse pharyngeal aspiration has been shown to produce an even 
distribution of administered materials throughout the lungs (Rao et al. 2003) and thus 
represents a noninvasive and physiologically relevant route of exposure to a specific dose in 
the lungs. Mice were euthanized to collect lung tissues on day 7 post-exposure.
Histopathology
Mice were euthanized by intraperitoneal injection of sodium pentobarbital (Zoetis, Florham 
Park, NJ, USA) at a dose of >100 mg/kg body weight. The left lung lobe was removed, fixed 
with 10 % neutral-buffered formalin through intratracheal perfusion, and embedded in 
paraffin. Sections of 5 μm thickness were subjected to H&E staining, Masson's Trichrome 
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staining, and Picro-Sirius red staining following standard protocols. Six samples in each 
treatment group were investigated.
Immunohistochemistry
Formalin-fixed, paraffin-embedded lung tissue sections (left lung lobe, 5 μm) were 
deparaffinized with three washes of xylene for 5 min each, rehydrated gradually with two 
washes of 100 % ethanol for 10 min each, two washes of 95 % ethanol for 10 min each, one 
wash of 70 % ethanol for 5 min, and two washes of deionized water for 5 min each. For 
antigen unmasking, sections were heated to boil in antigen unmasking solution, Citric Acid 
Based, pH 6.0 (Vector Laboratories, Burlingame, CA, USA) and then maintained at a sub-
boiling temperature for 10 min in a microwave oven. The slides were then cooled on bench 
top for 30 min, washed with deionized water for 5 min, and incubated with BLOXALL 
Endogenous Peroxidase and Alkaline Phosphatase Blocking Solution (Vector Laboratories) 
for 10 min at room temperature to block endogenous peroxidase activity. The assays were 
performed with ImmPRESS Polymer Detection system (Vector Laboratories), following 
instructions from the manufacturer. Peroxidase activities were detected with the peroxidase 
substrate ImmPACT NovaRED (Vector Laboratories), which generates positive staining 
with red color. The slides were then counterstained with Hematoxylin QS (Vector 
Laboratories), which visualizes nuclei with blue–violet color. The primary antibodies used 
included anti-collagen I (Abcam, Cambridge, MA, USA), anti-FN1 (Abcam), anti-LCN2 
(Abcam), anti-SLPI (Thermo Fisher Scientific), anti-TNC (GeneTex, Irvine, CA, USA), and 
anti-collagen VI (Abcam). Images were photographed using Olympus Provis AX-70 system 
(Olympus, Center Valley, PA, USA). Four samples in each treatment group were 
investigated.
Immunoblotting
Lung tissue samples were homogenized in CelLytic MT Cell Lysis Reagent (Sigma, St. 
Louis, MO, USA) containing complete Protease Inhibitor Cocktail Tablets (Roche, Basel, 
Switzerland), followed by incubation on ice for 30 min with shaking, and centrifugation at 
14,000 rpm for 20 min at 4 °C to remove cell debris. The supernatant containing the whole 
protein extract was obtained, of which 20 μg was resolved in SDS-PAGE gel, transferred to 
PVDF membrane (EMD Millipore, Billerica, MA, USA), blocked with SuperBlock T20 
(PBS) Blocking Buffer (Thermo Fisher Scientific) at room temperature for 1 h, incubated 
with primary antibody at 4 °C overnight, incubated with horseradish peroxidase-conjugated 
secondary antibody at room temperature for 1 h, and detected using Amersham ECL Prime 
Western Blotting Detection Reagent (GE Healthcare Life Sciences, Little Chalfont, 
Buckinghamshire, UK). GAPDH was detected as an internal control. The primary antibodies 
used were anti-LCN2 (Abcam), anti-SLPI (Thermo Fisher Scientific), anti-TNC (GeneTex), 
anti-SPP1 (R&D Systems, Minneapolis, MN, USA), anti-MMP2 (Santa Cruz 
Biotechnology, Dallas, TX, USA), and anti-GAPDH (Fitzgerald, Acton, MA, USA).
Microarray gene expression analysis
Total RNA was extracted from mouse lung tissue samples using RNeasy Mini Kit 
(QIAGEN, Valencia, CA, USA), during which genomic DNA was removed with the method 
of on-column DNase treatment. For each dose group, RNA samples from four mice, which 
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were randomly selected from six treated mice, were used to perform microarray analysis. All 
the RNA samples used for this assay reached the required quality, including (1) A260/A280 
ratio between 1.8 and 2.1; (2) A260/A230 ratio greater than 1.5; and (3) RNA Integrity 
Number (RIN) of 8 or greater evaluated by an Agilent 2100 Bioanalyzer. The synthesis of 
cRNA from total RNA using Illumina TotalPrep RNA Amplification Kit (Life 
Technologies, Carlsbad, CA, USA), hybridization to MouseWG-6 v2.0 Expression 
BeadChip (Illumina, San Diego, CA, USA), and raw data processing with Illumina HiScan 
Array Scanner and GenomeStudio software v1.9.0 (Illumina) were performed under a 
service at Yale Center for Genome Analysis (Yale University School of Medicine, New 
Haven, CT, USA). Microarray data analysis was carried out under a service at Yale 
Bioinformatics Resource (Yale University School of Medicine).
Statistical analysis of microarray data
Gene expression data generated by Illumina were imported into Partek® Genomics Suite™ 
(Partek Incorporated, 6.4). Raw data were processed in steps of background correction of the 
perfect match values, quintile normalization across all of the chips in the experiment, and 
median polish summarization. Within each condition, outliers were identified using 
principle component analysis (PCA) and excluded from all further analysis. Differentially 
expression analysis of the samples was performed using one-way analysis of variance 
(ANOVA). p values were adjusted for multiple comparisons using false discovery rate 
multiple testing correction (Benjamini and Hochberg 1995). Differentially expressed genes 
were selected with threshold of relative ± twofold change and adjusted p values ≤0.05. The 
heat map was generated using heatmap.2 function available in “gplots” package in R 
program. Venn diagrams were generated using VennDiagram package in R program.
Function and pathway analysis of differentially expressed genes
Canonical pathways and gene ontology (GO) biological processes associated with identified 
differentially expressed genes were disclosed using MetaCore GeneGO server (https://
portal.genego.com/). p values were calculated based on hypergeometric distribution and 
reflected the probability for a pathway or process to arise by chance. Pathways and 
processes with a Benjamini–Hochberg multiple testing correction p value of ≤0.05 were 
considered significant.
Transcription factor analysis
The network-building algorithm on transcription regulation from MetaCore was used to 
examine whether the identified genes were connected to transcription factors. For each 
candidate transcription factor, a p value was calculated based on hypergeometric 
distribution, indicating enrichment in the genes of interest. Transcription factors with 
Benjamini–Hochberg multiple testing correction p value of ≤0.05 were considered 
significant. Transcription regulation networks were built centering on the most significant 
transcription factors.
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Total RNA was extracted from mouse lung tissue samples using RNeasy Mini Kit and 
reverse-transcribed to produce cDNA using QuantiTect Reverse Transcription Kit (QIA-
GEN). qRT-PCR was performed and analyzed as described previously (Dong et al. 2015). 
The fold change values for three samples in each treatment group were averaged, and data 
were presented as the mean ± SD. Statistical evaluation of differences between treatment 
groups was determined by two-tailed Student's t test. A p value of less than 0.05 was 
considered statistically significant (*p < 0.05; **p < 0.01; ***p < 0.001).
Results
Pathologic features of lung lesions induced by prototypical particulate and soluble 
chemical fibrogenic agents
The development of induced lung fibrosis includes an acute-phase response upon fibrogenic 
agent exposure, followed by progression to chronic fibrosis, with drastically distinct 
pathologic features between the two phases. Among fibrogenic inducers, soluble chemicals, 
such as bleomycin and paraquat, selectively accumulate in the lungs and cause marked 
cytotoxicity to lung cells; on the other hand, agents with a bulky mass, such as inhaled 
particles, fibers, and microbes, stimulate tissue responses, such as Inflammation, without 
directly killing lung cells. Nonetheless, both types of inducers cause lung fibrosis in humans 
and animals, albeit with notable differences in pathologic manifestations. To elucidate the 
mechanism of lung fbrogenesis at the molecular level, we chose to analyze and compare the 
molecular events that control the transition from the acute-to-chronic progression during 
lung fbrosis induced by prototypical fibrogenic inducers, i.e., silica as an example of 
particulate inducers, and bleomycin and paraquat as examples of soluble chemical inducers. 
We investigated the genome-wide gene expression patterns on day 7 post-exposure, at which 
time the acute lesions appear to have reached a climax, and represent a junction for the 
acute-to-chronic transition and progression.
We first characterized the pathologic features of pulmonary lesions on day 7 post-exposure 
to silica, bleomycin, and paraquat at a dose of 2, 0.07, and 0.02 mg, respectively, by 
pharyngeal aspiration, in comparison with saline control. Histological examinations revealed 
dramatically increased cellularity and accumulation of matrix materials in the lung 
parenchyma of treated mice compared with saline control (Fig. 1A and data not shown). The 
lesions appeared similar in intensity among silica, bleomycin, and paraquat treatment 
groups, which provided a basis for comparison among the treatments at the molecular level 
in later analyses. In addition to inflammatory infiltration, the data revealed prominent 
fibrotic alterations in all three treatment groups, as demonstrated by the Masson's Trichrome 
staining (Fig. 1A, a–d), which distinguishes cells from their collagenous connective 
surroundings, and Picro-Sirius red staining (Fig. 1A, e–h), which preferentially detects 
collagens I and III, two major collagen fibers involved in lung fibrosis. The findings indicate 
that fibrotic changes occurred early and accompanied the acute inflammatory alterations.
Notable differences in the pathologic phenotypes induced by the agents were observed. The 
lesions resulting from silica exposure were characterized by a low-to-moderate level of 
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inflammatory infiltration, formation of nodule-like fibrotic foci, and intensive deposition of 
collagen fibers within the fibrotic foci (Fig. 1A, b and f), whereas the lesions induced by 
bleomycin or paraquat shared a higher degree of similarity between the two treatments than 
with silica and fell into the other group, featured with severe inflammatory infiltration and 
diffuse deposition of collagen fibers without prominent nodule-like fibrotic focus formation 
(Fig. 1A, c and g, d and h). Notably, bleomycin and paraquat induced marked tissue damage 
and, in the case of paraquat exposure, mild-to-moderate hemorrhagic lesions in early time 
points (data not shown), which is in agreement with the notion that both chemicals are 
highly cytotoxic to lung cells.
Collagen and fibronectin (FN1) are two major components of the extracellular matrix 
(ECM) and, therefore, serve as markers of fibrosis. To further validate the fibrotic responses 
induced by these fibrogenic agents, the protein levels and distribution patterns of collagen I 
and FN1 were examined by immunohistochemistry. The levels of both collagen I (Fig. 1B, 
a–d) and FN1 (Fig. 1B, e–h) were dramatically elevated in fibrotic lungs from mice exposed 
to silica, bleomycin or paraquat, compared with saline control. Moreover, collagen I and 
FN1 exhibited a more compact and focal pattern of distribution within the nodule-like 
fibrotic foci in the lungs exposed to silica (Fig. 1B, b and f), but a more diffusely distributed 
pattern was observed in the lungs exposed to bleomycin or paraquat (Fig. 1B, c and g, d and 
h). These findings confirmed that silica, bleomycin, and paraquat potently induced fibrotic 
responses in the lungs on 7 days post-exposure, with distinct morphologic features, in 
addition to commonly increased deposition of fibrotic matrix proteins, implicating both 
distinct and overlapping underlying mechanisms in the development of the induced lung 
fibrosis.
Genome-wide gene expression induced by fibrogenic agents
To analyze genome-wide gene expression, we performed microarray analysis of RNA 
samples from lungs of four mice from each of the saline, silica, bleomycin, or paraquat 
treatment group. Differentially expressed genes were identified using the criteria in which 
the p values with false discovery rate (FDR) were ≤0.05, and the up-regulated or down-
regulated fold changes in comparison with saline control were more than 2.0 following 
silica, bleomycin or paraquat exposure.
Treatment with silica affected the expression of 143 genes, in which 124 were up-regulated 
and 19 downregulated as compared with the saline control. Treatment with bleomycin or 
paraquat affected the expression of significantly more genes than silica treatment. In 
bleomycin-treated lungs, 247 genes were affected, including 170 up-regulated and 77 down-
regulated. Paraquat exposure resulted in modified expression of 299 genes with 205 genes 
up-regulated and 94 down-regulated. Heat map analysis of these differentially expressed 
genes is shown in Fig. 2A, and detailed expression levels of the genes are listed in Table S1. 
Figure 2B listed ten top genes with their fold changes, compared with saline control, from 
each treatment group, such as lipocalin-2 (Lcn2), secretory leukocyte peptidase inhibitor 
(Slpi), tenascin-C (Tnc), secreted phosphoprotein 1 (Spp1, osteopontin, OPN), matrix 
metalloproteinase (Mmp), and tissue inhibitor of metalloproteinases 1 (Timp1), which have 
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all been implicated in the pathogenesis of lung fibrosis and related lung diseases in humans 
and experimental animals.
These findings demonstrate that the treatments induced dramatic alterations in gene 
expression, indicating active transcription during the acute-to-chronic fibrotic transition in 
the lungs. Moreover, the heat map clearly revealed both shared and distinct gene expression 
patterns among the three treatment groups. There were apparently more similarities in gene 
expression between bleomycin and paraquat treatments than with silica treatment, and more 
genes affected by bleomycin or paraquat than by silica, which are consistent with the 
pathologic findings qualitatively.
Quantitative comparisons of the regulated genes were presented in Venn diagrams (Fig. 3A). 
Sixty-five genes were affected by all three treatments; 76 genes were affected by both silica 
and bleomycin; 80 genes were affected by both silica and paraquat; and 164 genes were 
affected by both bleomycin and paraquat. Several groups of genes were commonly induced 
by all three agents. In addition to fibrosis marker genes, such as Col1a1 (collagen 1a1) and 
Mmp2, genes functioning in cell proliferation and survival, such as Cdc20 and Birc5 
(survivin), and genes involved in DNA synthesis, damage, and repair, and chromatin 
architecture, such as the members of the Hist1h2a gene family, were found induced by 
silica, bleomycin, and paraquat, implicating proliferation and DNA metabolism as key 
common mechanisms of regulation at the level of gene transcription for lung fibrosis 
induced by all three inducers.
There were apparently groups of genes uniquely regulated by each treatment. The number 
and percentage of unique genes regulated were 52 (36.4 %) for the silica treatment, 72 (29.1 
%) for bleomycin, and 120 (40.1 %) for paraquat, respectively. For instance, among the 52 
genes distinctively induced by silica, a number of genes are involved in immune regulation 
and function, including Ccl3, Ccl4, Ccl6, Cxcl1, Il1rn, Il4i1, Csf2, Oas1g, and Oas2. The 72 
genes affected by bleomycin treatment only, including Cdkn1a, Ccng1, Egr1, Egr2, Ctsa, 
Ctsb, Ctsh, Cxcl13, and Ccr5, have been implicated in cell cycle control, mitogenesis, 
differentiation, protein turnover, or Inflammation. Paraquat regulated the expression of 120 
genes uniquely, some of which play important roles in mitosis and DNA replication, such as 
Aurka and Mcm2; ECM modification, such as Col6a1 and Mmp3; or inflammatory 
response, such as Ccl2.
Representative, commonly or uniquely induced genes are shown in Fig. 3B. Seven genes 
were induced by all three fibrogenic inducers; within these genes, induction of Lcn2 by 
silica was markedly higher than by bleomycin or paraquat, whereas induction of Col1a1 by 
paraquat was remarkably higher than by silica or bleomycin, and induction of Tnc and Spp1 
by bleomycin or paraquat was dramatically higher than by silica. Shown also in Fig. 3B are 
sets of three genes from the treatment groups that illustrate unique gene induction by each of 
the treatment agents. Therefore, there were both common and distinct gene expression 
patterns among the treatments and there was a higher degree of shared gene expression 
between bleomycin- and paraquat-treated groups than with the silica group.
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Differential mRNA and protein expression in induced lung fibrosis
We performed quantitative RT-PCR to further validate differential expression of the genes 
revealed by microarray analysis. Shown in Fig. 4A are the fold changes of mRNA induction 
of five representative genes. Col1a1 and Fn1 are fibrosis marker genes, and their mRNAs 
were induced significantly by all three inducers in qRT-PCR (Fig. 4A, upper panels), which 
correlated well with the mRNA induction revealed by microarray (Figs. 2B, 3B). Timp1 is a 
matrix remodeling enzyme secreted into the matrix from cells like myofibroblasts. Timp1 
was highly induced during lung fibrosis (Fig. 4A, lower left panel); induction by bleomycin 
and induction by paraquat were similar to each other but much higher than by silica, which 
correlated well with the microarray data (Fig. 2B). Lcn2 and Tnc were induced by all three 
treatments, but with distinct and opposite patterns of induction, as revealed by microarray 
analysis, wherein induction of Lcn2 was highest by silica, followed by bleomycin, and lastly 
by paraquat, but induction of Tnc was highest by paraquat, followed by bleomycin, and 
lastly by silica (Fig. 3B). The qRT-PCR analysis revealed similar patterns of induction of 
the two genes to those by microarray analysis (Fig. 4A, lower middle and right panels). 
Therefore, qRT-PCR revealed similar levels and patterns of mRNA induction of the genes to 
those from microarray analysis.
To verify whether the identified differential mRNA expression of the genes affected their 
expression at the protein level in lung tissues undergoing fibrosis, we performed 
immunohistochemical analysis for representative genes on lung sections from control and 
treatment groups.
LCN2, also known as neutrophil gelatinase-associated lipocalin (NGAL), is a member of the 
lipocalin family and functions as an iron-trafficking protein. LCN2 has been implicated in 
several critical biological processes, including innate immunity, cell proliferation, and 
apoptosis. Serum and urine LCN2 are considered as biomarkers for early diagnosis of acute 
kidney injury (Haase-Fielitz et al. 2014; Makris and Kafkas 2012) and cardiovascular 
disease (Iqbal et al. 2013). As Lcn2 was significantly induced by silica, bleomycin, or 
paraquat from the microarray analysis (Fig. 2B), we studied LCN2 protein expression in the 
lungs exposed to these fibrogenic agents. Compared with saline control, the LCN2 protein 
was induced significantly by silica, followed by paraquat, and by bleomycin at a mild, 
detectable level (Fig. 4B, a–d), which correlated with the mRNA expression data from 
microarray and qRT-PCR (Figs. 3B, 4A) qualitatively. The data indicated that the level of 
LCN2 protein was increased by fibrogenic agents, though at variable levels, and suggest that 
LCN2 might play a role in the onset of Inflammation and induced fibrosis in the lungs.
SLPI is a potent inhibitor of proteolytic enzymes including the neutrophil proteases and 
elastase. SLPI plays an important role in anti-protease defense and exhibits anti-
inflammatory, anti-bacterial, and anti-viral activities in the lungs (McKiernan et al. 2011; 
Zani et al. 2011). SLPI inhibits NF-κB-mediated pro-inflammatory gene expression, which 
may account for its anti-inflammatory function in the lungs (Taggart et al. 2005; Weldon 
and Taggart 2007). The SLPI protein level was elevated in the lungs exposed to all three 
fibrogenic agents, but induction was the highest by silica, followed by paraquat, and lastly 
by bleomycin, compared with saline control (Fig. 4B, e–h), which differed from the 
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microarray data where the mRNA of Slpi was significantly induced by silica, but not much 
by paraquat or bleomycin comparatively (Fig. 3B).
TNC is an ECM protein highly expressed in a number of pathological conditions, such as 
chronic Inflammation and cancer, and during tissue repair following tissue injury and 
infection. TNC functions in ECM remodeling, cell migration and proliferation, and signal 
transduction, presumably through its interaction with other ECM molecules and cell surface 
receptors (Midwood et al. 2011; Udalova et al. 2011). TNC expression was not detected in 
the lungs exposed to saline (Fig. 4B, i), but paraquat induced TNC to a dramatically high 
amount, and silica and bleomycin induced TNC at lower levels than paraquat (Fig. 4B, j–l), 
which correlated well with the microarray and qRT-PCR data. This finding is consistent 
with previous reports in which TNC was induced and was involved in fibrotic diseases 
(Carey et al. 2010; Estany et al. 2014). Therefore, TNC potentially serves as a candidate for 
a role in the mechanism of induced lung fibrosis.
Collagen VI was reported to be induced during lung fibrosis, but its regulation and function 
in fibrosis remain largely unclear (Specks et al. 1995). Collagen VI is an ECM protein and is 
a major structural component of microfibrils. The expression and accumulation of collagen 
VI protein were induced at a detectable but mild level in the lungs exposed to silica; at a 
moderate level by bleomycin; and at a considerably high level by paraquat (Fig. 4B, m–p). 
Thus, collagen VI induction appeared to be more significantly induced by paraquat 
treatment than by bleomycin and silica.
Induction of protein expression was also examined by immunoblotting (Fig. 4C). The 
overall protein level of LCN2 in the lungs was induced dramatically by silica and slightly by 
bleomycin and paraquat, which is consistent with the results from immunohistochemical 
staining (Fig. 4B, a–d). The SLPI level was induced by silica and paraquat, but not by 
bleomycin, in the whole protein extract from lung tissues, indicating a limited effect of 
bleomycin on SLPI protein expression. The TNC level was significantly elevated in the 
lungs exposed to bleomycin and paraquat, but was only slightly elevated by silica, which is 
in agreement with the results detected by immunohistochemistry (Fig. 4B, i–l). MMP2 
functions in the breakdown of ECM and has been shown to play an anti-fibrotic role 
(Giannandrea and Parks 2014; Tan et al. 2006). Mmp2 gene transcription was induced by 
silica, bleomycin, and paraquat (Fig. 3B). Here, we showed that the level of MMP2 protein 
was greatly increased by the three inducers. SPP1 (OPN) has been reported to be induced 
and to function during wound healing and fibrosis in multiple tissues and organs including 
the skin, liver, and heart (Leung et al. 2013; Matsui et al. 2004; Mori et al. 2008). The SPP1 
level was increased in peripheral blood mononuclear cells and the bronchoalveolar lavage 
fluid from IPF patients (Desai et al. 2011; Pardo et al. 2005), as well as mouse lungs 
exposed to bleomycin (Berman et al. 2004). We found that the transcription level of Spp1 
was induced by bleomycin or paraquat for more than tenfold; the Spp1 level was also 
increased by silica for 3.839-fold, though the p value with FDR of silica-treated group was 
higher than 0.05 (Fig. 3B). The SPP1 protein was induced dramatically by paraquat, at a 
moderate level by bleomycin, and at a mild but detectable degree by silica.
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Taken together, these data revealed that, overall, the protein levels of the genes tested in the 
lungs correlated qualitatively with the expression of the proteins in fibrotic regions revealed 
by immunohistochemistry and expression of their mRNA revealed by microarray and qRT-
PCR. One exception was Slpi, which showed strong induction at the protein level by all 
three inducers by immunohistochemistry; however, at the mRNA level, it was significantly 
induced by silica, but only mildly by bleomycin and paraquat. The mechanism(s) 
responsible for these differential effects of the treatments on the mRNA and protein 
expression levels of Slpi remains to be studied.
Shared and distinct pathways and functions activated in induced lung fibrosis
To understand the roles of the differentially regulated genes in lung fibrosis, we analyzed the 
signaling pathways and associated functions of the genes. We first employed canonical 
pathway identification for each treatment group. The top ten statistically significant 
pathways from exposure to each fibrogenic agent are listed in Fig. 5A. Several features are 
notable. First, a number of pathways important for cell cycle control were activated by the 
treatments (three for silica, three for bleomycin, and six for paraquat). Among these 
pathways, two pathways involving cell cycle regulation through the anaphase-promoting 
complex (APC) or spindle assembly and chromosome separation were common to all three 
treatments (Fig. 5A, marked by a in dark red). One pathway involving metaphase checkpoint 
regulation was common to silica and paraquat (marked by b in bright blue), and one 
pathway involving NIMA (never in mitosis gene a)-related kinase (NEK) was identical in 
the bleomycin and paraquat groups (marked by c in dark green). Second, five pathways of 
immune responses involving interferon, Toll-like receptor (TLR), alternative complement 
activation, substance P, and prostaglandin E2 (PGE2) functions and signaling were activated 
by silica (marked by d in purple), and one pathway of immune response involving C1q was 
activated by bleomycin (marked by d in purple). Third, several other pathways involving 
cell adhesion and ECM remodeling, hematopoietic stem cell function, chemokines and 
adhesion, or platelet activation were activated by bleomycin or paraquat, among which three 
pathways were activated by both agents (marked by e in bright red).
These findings indicate that, within the top ten pathways activated by the fibrogenic agents, 
cell cycle control and proliferation were commonly activated by all three agents, which is in 
agreement with the conclusion from comparative analysis of differentially expressed genes, 
where Birc5, Cdc20, and the Hist1h2a family of genes were shown to be up-regulated by all 
three inducers, to impact cell proliferation and survival, DNA synthesis, and chromatin 
regulation. However, certain pathways and functions were preferentially activated by one or 
two agents. Silica preferentially stimulated innate immune functions (five out of ten 
pathways), whereas bleomycin and paraquat displayed more features shared with each other 
in activating functions relating to cell adhesion, platelet activation, and ECM remodeling. 
Between bleomycin and paraquat treatments, paraquat activated more cell cycle control 
functions than bleomycin (six vs. three pathways). Therefore, these three fibrotic agents 
activated both overlapping and distinct canonical pathways at the junction of acute-to-
chronic transition during lung fibrosis.
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Next, we performed gene ontology (GO) enrichment analysis to identify the cellular 
processes in which the proteins encoded by these genes are involved. Figure 5B displays the 
GO analysis of the up-regulated genes from each treatment group, listing the top ten 
statistically significant cellular processes activated by each treatment. Unlike the canonical 
pathway results, in which considerable overlap among the treated groups was observed, the 
GO cellular process study revealed more distinct patterns of effect from exposure to each 
agent, with the majority of the cellular processes being unique to a specific agent, and only 
three processes being shared between any two treatment groups (Fig. 5B, marked by a in 
dark red, b in bright blue, and c in dark green, respectively).
However, similarly to the canonical pathway analysis, the GO data showed that silica 
preferentially activated immune functions (four out of ten, marked by d in purple), whereas 
bleomycin and paraquat preferentially activated processes involved in ECM remodeling and 
collagen catabolism (marked by e in bright red). Paraquat also preferentially activated cell 
cycle regulation processes (marked by f in black). In addition, a number of responses related 
to defense against other organisms or foreign bodies were found activated by silica (five out 
of ten GO processes, marked by g in bright green) and a response to wounding was activated 
by bleomycin (marked by h in yellow), which presumably reflect the nature of silica as a 
foreign body with bulky mass and that of bleomycin as a cell killing and tissue wounding 
agent. The GO analysis clearly demonstrated that the cellular effects and biological 
consequences induced by these fibrogenic agents can be diverse and distinctive, which may 
reflect the unique mode of action by each agent in the lungs.
Upstream transcription factors and signaling networks activated by fibrogenic inducers
We further analyzed the mechanisms by which the inducers modulate the expression of the 
genes by identifying major upstream transcription factors and signaling networks through a 
transcriptional network analysis. The biological networks affected by each fibrogenic agent 
were identified based on p values and z-scores, and the top five networks for each treatment 
group are shown in Fig. 6. The top five most affected transcriptional networks for silica 
treatment were CREB1, c-Myc, RelA (p65 NF-κB subunit), STAT1, and SP1 (Fig. 6, top 
panel); for bleomycin treatment, SP1, CREB1, c-Myc, RelA (p65 NF-κB subunit), and p53 
(middle panel); and for paraquat treatment, CREB1, SP1, c-Myc, p53, and E2F1 (bottom 
panel). Thus, the CREB1, SP1, and c-Myc networks were activated by all three fibrogenic 
inducers; RelA (p65 NF-κB subunit) was preferentially activated by silica and bleomycin; 
and p53 was preferentially activated by bleomycin and paraquat. In addition, STAT1 was 
activated in the silica-exposed group, and E2F1 was activated in the paraquat-treated group.
CREB1, SP1, c-Myc, p53, and E2F1 are known to be important regulators of cell growth, 
differentiation, and survival (marked in blue dashed rectangles), whereas transcription 
factors RelA (p65 NF-κB subunit) and STAT1 play important regulatory functions in 
immune responses (marked in pink dashed rectangles). The findings from the top five 
transcription factor networks activated by each agent suggest that: (a) all three agents 
activate transcription factors CREB1, SP1, and c-Myc to boost cell proliferation and 
survival; (b) silica activates the RelA and STAT1 pathways of gene transcription, which 
may account for its preferential activation of immune functions; and (c) bleomycin and 
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paraquat share more transcriptional pathways than with silica, and both activate more 
transcriptional networks relating to cell cycle control and DNA damage response than silica, 
consistent with their apparent cytotoxicity.
In addition to the major transcription factors, Fig. 6 revealed dysregulated upstream 
signaling networks, the interrelationship among the regulatory factors, and the cellular 
localization of the factors, for each treatment. In this respect, the analysis has integrated 
functional molecules and pathways affected by each agent to provide a comprehensive 
presentation of the mechanisms of gene regulation by particulate and soluble chemical 
fibrogenic inducers that drive the transition from acute inflammation to chronic fibrosis 
during the development of lung fibrosis.
Discussion
Induced lung fibrosis in animals has served as experimental models for examining and 
understanding the occurrence and progression of human lung fibrotic diseases, including 
induced lung fibrosis like silicosis and idiopathic lung diseases like IPF. IPF has drawn a 
great attention in the past decades because the onset of this disease leads to a short survival 
time and a high fatality rate in patients, which is in part due to a lack of effective drug 
treatment. Several factors have been shown to significantly increase the risk of developing 
IPF, including cigarette smoke and a number of environmental and occupational exposures 
such as wood, coal, and hay dusts (Olson and Swigris 2012). In addition to IPF, several 
other human diseases, such as sarcoidosis and scleroderma, are also idiopathic in origin and 
have progressive lung fibrosis as a severe form of pathologic development and cause of 
mortality, though other organ systems may also be involved. Identifying the risk factors and 
mechanisms involved in the development of induced or idiopathic human lung fibrotic 
lesions is a necessary step for understanding their pathogenesis and for effective therapy and 
prevention against the diseases.
Several experimental lung fibrosis models, such as those induced by particles (silica) and 
fibers (asbestos), and those by soluble chemicals (bleomycin and paraquat), have been 
commonly used to examine mechanisms of lung fibrosis. The pathologic features of these 
models differ significantly from one another with each model only partially mimicking IPF. 
Furthermore, fibrogenic inducers display distinct modes of action upon entering the lungs, 
wherein soluble chemicals, like bleomycin and paraquat, directly kill lung cells, but 
insoluble particulate inducers, such as silica, likely stimulate tissue responses as a major 
mode of action to trigger fibrogenesis. Therefore, comparing among experimental models of 
lung fibrosis that have distinct pathologic features and are induced by fibrogenic agents with 
different modes of action would real new aspects of the pathogenesis and development of 
human lung fibrotic diseases like IPF.
It is known that induced experimental lung fibrosis commonly includes an acute-phase 
response characterized by acute inflammatory infiltration and tissue damage, and a chronic 
phase progression marked by interstitial fibrosis and granuloma formation; this finding 
suggests that common, but as-yet-unidentified, mechanisms or programs may exist and 
dictate the biphasic responses and the progression from acute-to-chronic fibrosis 
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development, at the molecular level. From these considerations, we used microarray gene 
expression assay and computational data analysis to dissect and compare lung fibrosis 
models induced by silica, bleomycin, or paraquat, in order to elucidate the common and 
inducer-specific mechanisms critical for lung fibrosis development. We chose day 7 post-
exposure as the time point for the analyses, because it represents the time point at which the 
peak acute responses to silica, bleomycin, and paraquat exposures take place and, thus, 
reflects a junction of transition for the acute-to-chronic pathologic progression.
Differentially expressed genes were identified that discern the effects of each fibrogenic 
agent (Figs. 2, 3; Table S1). Through comparison among the genes regulated by silica, 
bleomycin, or paraquat, the genes were separated into three groups: (a) those commonly 
regulated by three agents; (b) those commonly regulated by two agents; and (c) those 
uniquely regulated by one agent (Figs. 2A, 3A). Differential gene expression in fibrotic 
lungs was confirmed at the mRNA level by qRT-PCR and at the protein level by 
immunohistochemistry and immunoblotting for several selected groups of genes (Fig. 4). 
Analyses of canonical pathways, gene ontology, and upstream transcription factors and 
signaling networks confirmed the findings of the gene analyses and, more importantly, 
provided insightful information on the organization structure, signal transduction, function, 
and transcriptional regulation of the genes in the context of lung fibrosis (Figs. 5, 6).
A major finding of the gene expression study was the identification of genes and pathways 
commonly regulated by all three inducers; remarkably, a large number of these genes and 
functions are critically involved in cell cycle control, cell proliferation and survival, DNA 
dynamics, and chromatin regulation. Among these genes, Birc5 (survivin), Cdc20, Cdca3, 
Cdca8, and Cdkn3 regulate cell proliferation and survival, whereas nine members of 
Hist1h2a gene family that were up-regulated encode histone H2A and thereby play 
important roles in DNA synthesis, DNA damage and repair, chromatin architecture, cell 
cycle regulation, and cell proliferation and survival. Consistent with this notion, the 
canonical pathways involving APC and the spindle assembly and chromosome separation 
were commonly activated by all three inducers to mediate cell cycle control and cell 
proliferation. At the transcriptional level, all three fibrosis inducers stimulate the activation 
of gene transcription by c-Myc, CREB1, and SP1, transcription factors known to boost cell 
cycle control and proliferation, through specific upstream signaling networks.
During wound healing, fibroblasts are activated to proliferate and differentiate into 
myofibroblasts to secrete matrix proteins and cause contraction of repaired tissues; other 
cells, such as lung bronchial and alveolar epithelia and vascular cells, may also undergo 
vigorous proliferation for tissue repair and remodeling. By analogy with these findings on 
wound healing, it is believed that the fibroblastic proliferation following a fibrogenic 
stimulation is a critical mechanism for the development of lung fibrosis. Indeed, many 
fibrogenic inducers stimulate fibroblast proliferation in vitro. However, data obtained from 
in vivo study of fibroblast proliferation in lung fibrosis have been inconclusive, which may 
reflect the fact that, during lung fibrosis, fibroblasts and other lung cells may undertake a 
dynamic life cycle of proliferation, differentiation, and turnover, in a fibrotic stage-
dependent manner during the development of lung fibrosis; therefore, the time point at 
which cell proliferation is examined after exposure would be critical for detection and 
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quantification of cell proliferation in vivo. In this regard, our finding on the robust gene 
regulation relating to cell proliferation at the junction of transition from acute inflammation 
to chronic fibrosis provides a rational explanation to the role of cell proliferation and 
regulation during lung fibrosis induced by particulate and soluble chemical inducers, which 
may also be applicable to other forms of lung fibrosis including IPF.
A recent finding reveals that acute DNA damage induced by bleomycin significantly 
increased the relative nuclear abundance of histone H2A family in primary human HCA2 
fibroblasts (Lopez et al. 2012). This observation indicates that fibrogenic agents may confer 
cytotoxicity through generating genotoxic effects, which is consistent with the previous 
finding that bleomycin exposure induced single- and double-strand DNA breaks, through 
which it resulted in cytotoxicity and cell death in the lungs (Huang et al. 1981; Tounekti et 
al. 1993). Therefore, induction of the Hist1h2a gene family by cytotoxic inducers like 
bleomycin and paraquat would be part of the response to DNA strand breaks induced by the 
inducers. How this mechanism of Hist1h2a gene family induction is applied to silica-
induced lung fibrosis in animals and silicosis in humans remains to be studied.
The differentially expressed genes uniquely regulated by silica, bleomycin, or paraquat were 
identified, which facilitates the understanding of the mechanistic pathways that potentially 
lead to lung fibrosis induced by a specific agent. Among the 52 genes uniquely induced by 
silica, it is evident that a number of these genes play important roles in immune responses, 
including Ccl3, Ccl4, Ccl6, Cxcl1, Il1rn, Il4i1, Csf2, Oas1g, and Oas2. This finding is 
further supported by subsequent analyses, which revealed consistently that the silica 
treatment preferentially activated several canonical pathways and gene ontogeny processes 
related to immune response and regulation, as well as the transcriptional networks of NF-κB 
and STAT1, transcription factors known to play key roles in immune and inflammatory 
responses. In addition, silica stimulated a number of defense responses and functions, some 
of which are related to exposure to bulky masses, such as microorganisms and particles.
The above findings may have important implications for silicosis and lung fibrosis in 
humans. It is known that both innate and adaptive immune responses play important roles in 
fibrogenesis (Wynn and Ramalingam 2012). Therefore, an early activation of the immune 
system might be one of the mechanisms mediating silica-induced lung fibrosis. A portion of 
silicosis patients manifests apparent autoimmune symptoms or diseases, including nephritis, 
scleroderma, and systemic lupus erythematosus, in addition to lung fibrosis; moreover, in 
experimental animals, silica exhibits adjuvant effects on immune functions (NIOSH 2002; 
Parks et al. 1999). Whether the differentially regulated immune response genes by silica 
identified in the mouse model can be linked to silica's autoimmune effects observed in 
human patients with silicosis remains to be examined. In addition, silicosis is commonly 
accompanied by mycobacterial infection, such as tuberculosis, as a major clinical 
complication (NIOSH 2002). In addition to immune functions, we found silica preferentially 
activated the defense responses against other organisms and stresses. It remains to be 
examined how silica-induced alterations of gene expression, signaling pathways, and 
functions involved in immune response and defense contribute to this altered susceptibility 
to mycobacterial infection in patients with silicosis. Nevertheless, our findings on the 
regulation of immune and defense functions by silica provide an experimental approach to 
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studying the effect of silica on immune regulation and its role in the development of lung 
fibrosis, autoimmune dysfunction, and mycobacterial complication in humans.
Bleomycin and paraquat share more features with each other than with silica in regard to 
their modes of action and pathologic features in lung fibrosis. Both chemicals selectively 
accumulate in the lungs, regardless of route of exposure; both are highly cytotoxic to lung 
cells in which they accumulate; and both induce diffusive fibrosis in the lungs that is 
progressive and lethal in humans. There are also notable differences between bleomycin- 
and paraquat-induced lung fibrosis. Namely, bleomycin kills cells by causing DNA strand 
breaks through an as-yet-unclear mechanism, whereas paraquat undergoes redox cycling 
upon entering cells to produce a large amount of ROS in lung cells and, thereby, results in 
oxidative lesions and cell death. Pathologically, paraquat may induce extensive hemorrhage 
in addition to cell death in the lungs compared with bleomycin treatment.
Our analyses of gene expression in the lungs exposed to bleomycin and paraquat uncovered 
both overlapping and unique patterns of gene expression and activation of pathways and 
transcriptional signaling networks, which appeared to be in a good agreement with their 
modes of action and pathology in the lungs. Firstly, there were apparently more genes 
affected by bleomycin and paraquat treatments than by silica treatment, which may reflect 
the fact that both bleomycin and paraquat caused more significant cell death and tissue 
damage in the lungs than silica, which would provoke more cell proliferation and repair 
activities, resulting in more active gene transcription. Secondly, there were more shared 
genes, pathways, gene ontology, and transcription factors activated between bleomycin and 
paraquat treatments than with silica treatment. For instance, both bleomycin and silica 
activated pathways implicated in cell adhesion, platelet activation, and ECM remodeling 
(Fig. 5) and both activated the p53 transcription network (Fig. 6); this latter effect on p53 
may reflect the DNA damaging capability of the chemicals. Between bleomycin and 
paraquat treatments, paraquat activated more cell cycle control functions than bleomycin.
The analyses also revealed considerable numbers of genes uniquely regulated by bleomycin 
or paraquat. Seventy-two genes were affected by bleomycin alone, including Cdkn1a, 
Ccng1, Egr1, Egr2, Ctsa, Ctsb, and Ctsh. These genes are involved in certain fundamental 
processes, such as cell cycle regulation, mitogenesis, differentiation, and cellular protein 
turnover. Additionally, bleomycin uniquely induced the transcription of Cxcl13 and Ccr5, 
which function in inflammatory response. One hundred and twenty genes were uniquely 
regulated by paraquat, such as Aurka, Aurkb, Mcm2, Mcm6, and Mcm10, which play 
critical roles in mitosis and DNA replication; Col3a1, Col6a1, Col16a1, Col18a1, Mmp3, 
and Mmp13, which function in ECM modification; and Ccl2 and Ccl7, which are involved 
in inflammatory response. These findings provide new clues to understanding the molecular 
mechanisms underlying fibrotic responses specifically to bleomycin or paraquat exposure in 
the lungs.
In aggregate, our data from this study reveal a number of new and important patterns, 
pathways, and mechanisms of gene regulation that are commonly or uniquely activated at 
the junction of transition from acute inflammation to chronic fibrosis during the 
development of lung fibrosis induced by silica, bleomycin, or paraquat in vivo. The results 
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provide a comprehensive and integrated understanding of the regulation and signal 
transduction of the pathways and functions affected by the fibrogenic agents to induce 
fibrosis, especially for the transition of acute-to-chronic pathologic development in the 
lungs. The findings would aid in the study to understand and treat lung fibrogenesis in 
human lung fibrotic diseases, including both induced lung fibrosis, such as silicosis and 
those induced by chemical toxicity or mycobacterial infection, and idiopathic diseases, such 
as IPF, sarcoidosis, and scleroderma.
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FDR False discovery rate
FN1 Fibronectin
Dong et al. Page 20















IPF Idiopathic pulmonary fibrosis
Lcn2 Lipocalin-2
Mmp Matrix metalloproteinase
MWCNT Multi-walled carbon nanotubes
NEK NIMA (never in mitosis gene a)-related kinase
NF-κB Nuclear factor-κB





ROS Reactive oxygen species
Slpi Secretory leukocyte peptidase inhibitor
Spp1 Secreted phosphoprotein 1
Timp1 Tissue inhibitor of metalloproteinases 1
TLR Toll-like receptor
Tnc Tenascin-C
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Induced lung fibrosis and expression of fibrosis marker proteins. Wild-type C57BL/6J mice 
received saline vehicle control, silica (2 mg), bleomycin (0.07 mg), or paraquat (0.02 mg) 
and were killed on day 7 post-exposure. A Total collagen fibers were detected by Masson's 
Trichrome staining of lung tissue sections, with collagen fibers stained blue (a–d, scale bar 
50 μm). Collagen I and III fibers were visualized by Picro-Sirius red staining, with collagen 
fibers stained red (e–h, scale bar 50 μm). B Collagen I (a–d) and FN1 (e–h) levels were 
determined by immunohistochemistry on lung sections. Red indicates positive staining, and 
blue indicates nuclear counterstaining (scale bar 20 μm)
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Differential gene expression revealed by microarray. Genome-wide gene transcription 
profiling was obtained by microarray gene expression analysis on RNA samples isolated 
from the lungs exposed to fibrogenic agents for 7 days (n = 4 for each group). The genes 
possessing p value with FDR ≤ 0.05, and the either up-regulated or down-regulated fold 
change, compared with saline-treated control group, more than 2.0 following silica, 
bleomycin, or paraquat exposure, were identified and studied. A A heat map was generated 
for the differentially expressed genes. In the heat map, up-regulated genes were arranged in 
the upper part, and down-regulated genes in the lower part. Within each of these two parts, 
the common genes affected by all three agents, i.e., silica, bleomycin, and paraquat, were 
listed first; the common genes affected by any two agents, i.e., silica and bleomycin, or 
silica and paraquat, or bleomycin and paraquat, were listed secondly; and the unique genes 
that were only affected by one agent, i.e., silica, bleomycin, or paraquat, were listed last. 
Red, white, and blue indicate high, medium, and low expression levels, respectively. B 
Examples of up-regulated genes for each treatment group were shown with fold changes 
(mean ± SD, n = 4)
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Shared and unique patterns of gene expression in induced lung fibrosis. A Venn diagram 
analysis determined the similarity and distinctiveness among the genes affected by silica, 
bleomycin, or paraquat. B Among up-regulated genes, five genes that were commonly 
induced by three agents, and three genes that were uniquely induced by each specific agent, 
were selected to present with fold changes as examples (mean ± SD, n = 4). For Tnc and 
Spp1, the genes were induced by bleomycin and paraquat to much higher levels than by 
silica, where # indicates p value with FDR > 0.05
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Induction of gene expression in fibrotic lung tissues. A Quantitative RT-PCR analysis was 
performed and fold changes of mRNA levels relative to that of Gapdh were presented as 
mean ± SD (n = 3 for each group; *p < 0.05; **p < 0.01, ***p < 0.001). B Levels of LCN2 
(a–d), SLPI (e–h), TNC (i–l), and collagen VI (m–p) were determined on lung sections by 
immunohistochemistry (red, scale bar 20 μm). Blue indicates nuclear staining. C The levels 
of LCN2, SLPI, TNC, MMP2, and SPP1 in lung tissues were determined by 
immunoblotting; blotting results for two randomly selected samples from each group were 
presented as illustration. GAPDH was used as an internal control
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Comparison of signaling pathways and cellular processes activated by fibrogenic inducers. 
A Identification and comparison of activated canonical pathways. The top ten statistically 
significant pathways enriched by the exposure to each fibrogenic agent were presented. 
Shared and unique pathways activated by the agents were labeled with letters in colors as 
described under “Results”. B gene ontology (GO) enrichment analysis disclosed promoted 
cellular processes. The top ten statistically significant processes enhanced by each 
fibrogenic agent were presented. Shared and unique processes were marked with letters in 
colors as described under “Results”
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Upstream regulators and networks modulated by fibrogenic inducers. The top five 
statistically significant transcriptional regulation networks were identified and displayed for 
each agent. The regulators were presented in the cellular compartments or extracellular 
space where they play biological functions. The up-regulated molecules with fold changes 
≥3 were marked with dark red dots and <3 with light red dots, whereas the down-regulated 
molecules with fold changes ≤−3 were marked with dark blue dots and >−3 with light blue 
dots. The transcription factors mainly involved in cell growth, cell differentiation, and cell 
death were labeled with blue dashed rectangles, whereas those functioning in immune 
responses were labeled with pink dashed rectangles. The positive/activated relation between 
two regulators was shown with green line, negative/inhibitory relation with red line, and 
unspecified relation with gray line
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